Summary.-Growth of syngeneic transplants of a 3-methylcholanthrene induced rat sarcoma was suppressed when tumour cells were injected in admixture with BCG. Rejection of these mixed inocula resulted in the suppression of growth of a simultaneous challenge with cells of the same tumour at a contralateral subcutaneous site and conditions for immunotherapy were evaluated with respect to the maximum tumour cell challenge rejected and the optimum time of treatment. These studies" established that viable tumour cells were more effective than radiation attenuated cells for the immunizing stimulus. Also, the maximum tumour challenge totally rejected in this way was of the order of 106 cells, and with this rapidly growing tumour, treatment had to be initiated within 4 days of tumour injection. These observations are relevant to current proposals for adjuvant immunotherapy of human malignant disease where conditions of minimal residual disease are not being fulfilled.
IMMUNOTHERAPY is now being viewed as a feasible component of the treatment of human malignant disease. This is based firstly upon the evidence that many cancer patients elicit an immune response against neoantigens associated with their own tumours as demonstrated by the in vitro cytotoxicity of peripheral lymphocytes for cultured tumour cells (Hellstr6m et al., 1971) . Secondly, immunostimulation by nonspecific adjuvants such as Bacillus Calmette-Guerin (BCG) and Corynebacterium parvum has been used to induce rejection or to retard growth of syngeneic transplants of a number of experimental animal tumours (Mathe, Pouillart and Lapeyraque, 1969; Parr 1972; Bansal and Sj6gren, 1973; Currie and Bagshawe, 1970; Woodruff and Boak, 1966) . Recent experimental investigations, however, have established that direct contact between viable BCG organisms and tumour cells produces a more marked suppression of tumour growth than that elicited by general immuno-20 stimulation. Thus syngeneic transplants of several tumours, including diethylnitrosamine induced guinea-pig hepatomata (Zbar, Bernstein and Rapp, 1971 ) and 3-methylcholanthrene induced sarcomata in rats (Baldwin and Pimm, 1971) and mice , are suppressed when tumour cells are injected locally in admixture with BCG. Infection of established tumours may also lead to their rejection Baldwin and Pimm, 1971) . In addition to the retardation of localized tumour development, BCG infection of subcutaneous grafts of a transplanted guinea-pig hepatoma prevented the development of lymph node metastases and similar treatment of a rat epithelioma restricted or retarded the formation of pulmonary metastases (Baldwin and Pimm, 1973a) . The rationale of directly contacting BCG with tumour cells has also been used to suppress the development of pulmonary metastases produced artificia]ly in rats by intravenous injection of sarco-mata cells (Baldwin and Pimm, 1973b) or developing spontaneously from a transplanted epithelioma (Baldwin and Pimm, 1973a) by subsequent intravenous injection of BCG.
The objective of the present studies, using a 3-methylcholanthrene (Mc) induced sarcoma with defined immunogenicity, was to evaluate the maximum tumour burden in terms of transplanted tumour cells which can be reproducibly treated by deliberate tumour infection with BCG. Rejection of sarcoma-BCG mixed inocula is known to induce suppression of growth of the same tumour implanted at another site (Baldwin and Pimm, 1971) In a further experiment, the influence of an increased dose of BCG (1.2 mg moist weight) on the growth of 7 5 X 107 sarcoma Mc7 cells was examined, but tumour takes (5/5) and growth rates were comparable with those in animals receiving tumour cells in admixture with the BCG freeze-drying medium.
Active immunotherapy of sarcoma Mc7
It has previously been demonstrated (Baldwin and Pimm, 1971) that rejection of a BCG-sarcoma Mc7 mixed cell inoculum resulted in suppression of a simultaneous challenge with 5 x 105 cells of the same Having established that active immunotherapy of sarcoma Mc7 could control tumour growth from challenge inocula of 2 X 105 to 1 X 106 cells, further experiments were carried out to determine the effect of delaying treatment for several days after challenge with Mc7 cells (Table II) . In the experiment illustrated in Fig. 2 ,tg moist weight). These treatment inocula of tumour cells and BCG consistently failed to develop, even when the contralateral challenge inocula were too large to be controlled. Immunotherapy was also effective when initiated up to 4 days after tumour challenge, producing complete or partial regression of tumour growth but after 7 days, when the animals had developed palpable tumours, it was completely ineffective. Viable sarcoma cells mixed with BCG were more efficient for immunotherapy than comparable numbers of y-irradiated cells together with viable BCG organisms.
In comparable studies with an intradermally transplanted guinea-pig hepatoma, (Baldwin, Price and Robins, 1973) . In this context it should be noted (Fig. 2) that even in rats successfully treated by contralateral immunization with sarcoma cell-BCG inocula, tumours developed for a limited period at the challenge site before undergoing regression. These observations suggest that effective active immunotherapy is dependent upon subtle responses, possibly controlling the relative levels of sensitized lymphocytes and circulating blocking factors. This has been postulated by Bansal and Sjogren (1973) who correlated the influence of BCG therapy on growth inhibition of transplanted polyoma rat tumours with increased levels of cytotoxic lymphocytes. This effect was observed when BCG was given intracutaneously before or at the time of tumour implantation. Enhancement of tumour growth rather than suppression was observed when BCG was given at the time when palpable tumour nodules were present, and this correlated with an increased serum blocking activity and no great change in the level of cell mediated immunity. 
